Ftse Mib
39.046,00
0,86%
DAX
22.631,14
1,05%
S&P 500
5.955,25
-0,47%
NASDAQ
19.026,39
-1,35%
Bitcoin
88.841,56
0,24%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Regno Unito LSE Merck & Co Inc (0QAH) Merck & Co Inc (0QAH) Notizie

0QAH

Merck & (0QAH)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:LSE:0QAH
DataOraFonteTitoloSimboloCompagnia
04/02/202513:55Alliance NewsAlliance NewsMerck hits 2025 sales guidance; pauses Gardasil China shipmentsLSE:0QAHMerck & Co Inc
28/01/202522:20Alliance NewsAlliance NewsIN BRIEF: Merck announces USD10 billion share buyback authorisationLSE:0QAHMerck & Co Inc
28/01/202518:14Alliance NewsAlliance NewsIN BRIEF: Merck says HPV vaccines allegations "have no merit"LSE:0QAHMerck & Co Inc
18/12/202422:26Alliance NewsAlliance NewsMerck agrees USD1.9 billion deal with Hansoh to develop obesity drugLSE:0QAHMerck & Co Inc
11/12/202420:40Alliance NewsAlliance NewsIN BRIEF: Merck and AstraZeneca unveil long-term Lynparza resultsLSE:0QAHMerck & Co Inc
11/12/202417:02Alliance NewsAlliance News*Astrazencea and Merck & Co to continue trialling lynparza across multiple cancer typesLSE:0QAHMerck & Co Inc
11/12/202416:57Alliance NewsAlliance News*Merck & Co says lynparza linked to "clinically meaningful prolonged survival" of patientsLSE:0QAHMerck & Co Inc
11/12/202416:56Alliance NewsAlliance News*Astrazeneca partnered with Merck & Co on lynparza cancer treatment trialLSE:0QAHMerck & Co Inc
11/12/202416:51Alliance NewsAlliance News*Merck & Co notes positive results in phase-3 trial of Lynparza breast cancer treatmentLSE:0QAHMerck & Co Inc
12/11/202420:50Alliance NewsAlliance NewsIN BRIEF: Merck trial shows Koselugo effective in treating adultsLSE:0QAHMerck & Co Inc
31/10/202412:54Alliance NewsAlliance NewsMerck cuts earnings guidance as acquisitions weigh on bottom lineLSE:0QAHMerck & Co Inc
17/09/202421:15Alliance NewsAlliance NewsIN BRIEF: Merck and Daiichi Sankyo's patritumab effective in phase 3LSE:0QAHMerck & Co Inc
30/07/202413:59Alliance NewsAlliance NewsTOP NEWS: Merck swings to second-quarter profit; trims profit guidanceLSE:0QAHMerck & Co Inc
29/05/202415:22Alliance NewsAlliance NewsMerck & Co enhances ophthalmology portfolio with EyeBio acquisitionLSE:0QAHMerck & Co Inc
25/04/202413:13Alliance NewsAlliance NewsMerck & Co raises annual outlook thanks to first quarter boostLSE:0QAHMerck & Co Inc
15/03/202416:23Alliance NewsAlliance NewsIN BRIEF: Merck hails positive data on cervical cancer drug, KeytrudaLSE:0QAHMerck & Co Inc
20/02/202422:15Alliance NewsAlliance NewsMerck and Astellas drugs get priority review in US and JapanLSE:0QAHMerck & Co Inc
01/02/202413:57Alliance NewsAlliance NewsTOP NEWS: Merck books 2023 growth despite gefapixant rejection hitLSE:0QAHMerck & Co Inc
19/01/202412:29Alliance NewsAlliance NewsIN BRIEF: Arix Bioscience eyes USD19 million return from Harpoon saleLSE:0QAHMerck & Co Inc
08/01/202415:20Alliance NewsAlliance NewsMerck to buy Harpoon Therapeutics for about USD680 millionLSE:0QAHMerck & Co Inc
18/12/202312:04Alliance NewsAlliance NewsAstellas, Merck, Pfizer celebrate US approval for Keytruda plus PadcevLSE:0QAHMerck & Co Inc
15/12/202309:41Alliance NewsAlliance NewsMerck gets US FDA nod for Welireg, as trial with Moderna bears fruitLSE:0QAHMerck & Co Inc
11/12/202318:56Alliance NewsAlliance NewsMerck reports mixed updates for cancer treatment, KeytrudaLSE:0QAHMerck & Co Inc
26/10/202313:17Alliance NewsAlliance NewsTOP NEWS: Merck hails Daiichi Sankyo partnership but will take chargeLSE:0QAHMerck & Co Inc
20/10/202307:06Alliance NewsAlliance NewsTOP NEWS: Daiichi Sankyo soars on USD22 billion Merck cancer drug dealLSE:0QAHMerck & Co Inc
03/10/202318:00Alliance NewsAlliance NewsDrugmakers agree to US government price talks amid pushbackLSE:0QAHMerck & Co Inc
24/08/202317:24Alliance NewsAlliance NewsUPDATE: AstraZeneca, Merck & Co say Lynparza approved in JapanLSE:0QAHMerck & Co Inc
01/08/202313:49Alliance NewsAlliance NewsMerck & Co second quarter revenue up; profit falls acquisition costsLSE:0QAHMerck & Co Inc
16/06/202314:09Alliance NewsAlliance NewsMerck says latest trial data shows Keytruda meets survival endpointLSE:0QAHMerck & Co Inc
01/06/202314:44Alliance NewsAlliance NewsMerck and Astra's Lynparza prostate cancer treatment gets US approvalLSE:0QAHMerck & Co Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:LSE:0QAH

La tua Cronologia

LSE
PZ63
Bank Mont.26
BIT
UC4AYP
Unicredit Bank
COIN
RGTUSD
Rari Governance Token
BIT
UB5UKN
Unicredit Bank
LSE
HGT
Hg Capital
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci